Key result
Fludrocortisone reduction and heart failure therapy restore LVEF by ~30 points in Addison-associated cardiomyopathy.
Why the study?
The development of dilated cardiomyopathy as a rare cardiovascular manifestation of Addison's disease is poorly understood and infrequently reported.
Case Report (n=6)
Fludrocortisone titration may merit consideration in Addison-associated cardiomyopathy; this Level 5 case leaves open questions of causality and optimal management.
Addison's disease is often accompanied by a number of cardiovascular manifestations. We report the case of a 30-year-old man who presented with a new onset dilated cardiomyopathy due to Addison's disease. The clinical presentation, treatment, and outcomes of this rare hormone mediated cardiac disorder are reviewed.
No takes yet. Share an insight, caveat, or question.
Mozolevska et al. (2016) conducted a case report in Addison's disease with dilated cardiomyopathy (n=6). Fludrocortisone dose reduction and heart failure medical therapy was evaluated on Improvement in left ventricular ejection fraction (LVEF). In a 30-year-old male with Addison's disease, severe dilated cardiomyopathy triggered by fludrocortisone improved from 15% to 45% LVEF following dose reduction and heart failure treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: